Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis

Joint Bone Spine

Volumn 74, Issue 6, 2007, Pages 606-611

  Kvalvik, Anne Grimstvedt ^a   Lefsaker, Liv ^a   Dyvik, Siri ^a   Brun, Johan Gorgas ^b,c  

^a Haugesund Rheumatism Hospital   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

Anti TNF therapy; DAS28; Low disease activity; Quality improvement

Indexed keywords

INFLIXIMAB; METHOTREXATE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DISEASE ACTIVITY; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER FUNCTION TEST; LOW DRUG DOSE; MALE; MEDICAL SOCIETY; RHEUMATOID ARTHRITIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; TOTAL QUALITY MANAGEMENT; TREATMENT RESPONSE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 36749021502     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2007.04.009     Document Type: Article

References (40)

1. Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Burmester G.R., Bijlsma J.W., et al. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNF-alpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 64 Suppl 4 (2005) 2-14
2. Irvine S., and Capell H.C. Great expectations of modern RA treatment. Ann Rheum Dis 64 (2005) 1249-1251
3. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alfa monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 354 (1999) 1932-1939
4. Moreland L.W., Schiff M.H., Baumgartner S.W., Tindall E.A., Fleishmann R.M., Bulpitt K.J., et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 130 (1999) 478-486
5. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48 (2003) 35-45
6. Quinn M.A., Conaghan P.G., O'Connor P.J., Karim Z., Greenstein A., Brown A., et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52 (2005) 27-35
7. van der Heijde D., Klareskog L., Rodriguez-Valverde V., Codreanu C., Bolosiu H., Melo-Gomes J., et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54 (2006) 1063-1074
8. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
9. Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens P.J., Hazes J.M., et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52 (2005) 3381-3390
10. Zink A., Strangfeld A., Schneider M., Herzer P., Hierse F., Stoyanova-Scholz M., et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 54 (2006) 3399-3407
11. Fransen J., Stucki G., and van Riel P. The merits of monitoring: should we follow all our rheumatoid arthritis patients in daily practice?. Rheumatology (Oxford) 41 (2002) 601-604
12. Batalden P.B., Nelson E.C., and Roberts J.S. Linking outcomes measurement to continual improvement: the serial "V" way of thinking about improving clinical care. Jt Comm J Qual Improv 20 (1994) 167-180
13. Bansback N.J., Young A., and Brennan A. The NICE reappraisal of biologics in 2005: what rheumatologists need to know. Rheumatology (Oxford) 44 (2005) 3-4
14. Feltelius N., Fored C.M., Blomqvist P., Bertilsson L., Geborek P., Jacobsson L.T., et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 64 (2005) 246-252
15. Vrijhoef H.J., Diederiks J.P., Spreeuwenberg C., and Van der Linden S. Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis. Ann Rheum Dis 62 (2003) 419-422
16. Van Riel P.L., Van Gestel A.M., Scott D.L., and on behalf of the EULAR Standing Committee for International Clinical Studies Including Therapeutic Trials - ESCISIT. The EULAR handbook of clinical assessments in rheumatoid arthritis. Nijmegen, Alpen aan den Rijn (2000), van Zuiden Communications BV, The Netherlands
17. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31 (1988) 315-324
18. Felson D.T., Anderson J.J., Boers M., Bombardier C., Furst D., Goldsmith C., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38 (1995) 727-735
19. Kleinbaum D.G., Kupper L.L., and Muller K.E. Applied regression analysis and other multivariable methods (1988), PWS-Kent Publishing Company, Boston, MA
20. Parmar M.K.B., and Machin D. Survival analysis. A practical approach (1995), John Wiley & Sons, Chichester
21. Agresti A. An introduction to categorical data analysis (1995), John Wiley & Sons Inc., New York
22. Kvien T.K., Heiberg M.S., Lie E., Kaufmann C., Mikkelsen K., Nordvag B.Y., et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 23 (2005) S188-S194
23. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Coster L., et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52 (2005) 1986-1992
24. Geborek P., Bladstrom A., Turesson C., Gulfe A., Petersson I.F., Saxne T., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64 (2005) 699-703
25. Hyrich K.L., Watson K.D., Silman A.J., and Symmons D.P. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45 (2006) 1558-1565
26. Jacobsson L.T., Turesson C., Nilsson J.A., Petersson I., Lindqvist E., Saxne T., et al. Treatment with TNF-blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007) 670-675
27. Wallenius M., Rodevand E., and Skomsvoll J.F. Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis. Tidsskr Nor Laegeforen 125 (2005) 1664-1666
28. Wendling D., Materne G.E., Michel F., Lohse A., Lehuede G., Toussirot E., et al. Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. Joint Bone Spine 72 (2005) 309-312
29. Genta M.S., Kardes H., and Gabay C. Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community. Joint Bone Spine 73 (2006) 51-56
30. Ducoulombier V., Solau E., Coquerelle P., Houvenagel E., Siame J.L., Desprez X., et al. Long-term results of infliximab therapy in rheumatoid arthritis: experience acquired by the North-Pas-de-Calais hospital network. Joint Bone Spine 74 (2007) 56-59
31. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343 (2000) 1594-1602
32. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Furst D., Weisman M.H., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50 (2004) 1051-1065
33. Saint Marcoux B., and De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 73 (2006) 710-713
34. Agarwal S.K., Maier A.L., Chibnik L.B., Coblyn J.S., Fossel A., Lee R., et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 53 (2005) 872-878
35. Sidiropoulos P., Bertsias G., Kritikos H.D., Kouroumali H., Voudouris K., and Boumpas D.T. Infliximab treatment for rheumatoid arthritis, with dose titration based on the disease activity score: dose adjustments are common but not always sufficient to assure sustained benefit. Ann Rheum Dis 63 (2004) 144-148
36. Geborek P., Crnkic M., Petersson I.F., and Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 61 (2002) 793-798
37. Vander Cruyssen B., Van Looy S., Wyns B., Westhovens R., Durez P., Van den Bosch F., et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 8 (2006) R112
38. Finckh A., Simard J.F., Gabay C., and Guerne P.A. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 65 (2006) 746-752
39. Fransen J., Moens H.B., Speyer I., and van Riel P.L. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Ann Rheum Dis 64 (2005) 1294-1298
40. Grigor C., Capell H., Stirling A., McMahon A.D., Lock P., Vallance R., et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364 (2004) 263-269